CentryMed Pharmaceutical is focused on the development of innovative biotherapeutics, particularly antibody-based treatments aimed at addressing unmet medical needs in cancer and autoimmune diseases. The company specializes in designing bispecific and trispecific antibodies that can selectively target cancer cells while navigating the immunosuppressive environments often found in solid tumors. This approach includes the use of proprietary formats such as HBiAb (H-shaped bispecific antibody) and iBiAb (i-shaped bispecific antibody), which are engineered to optimize antigen-binding activities. By utilizing nonstructural polypeptide linkers of varying lengths and compositions, CentryMed aims to enhance therapeutic efficacy while minimizing potential toxicity, thereby creating larger therapeutic windows for patients.

In addition to its focus on antibody engineering, CentryMed is actively advancing a diverse pipeline of products currently in preclinical development. The company is working on multiple candidates targeting various types of solid tumors and other indications, including monoclonal antibodies and bispecific T cell engagers. CentryMed emphasizes the importance of collaboration and partnerships with other pharmaceutical companies and research institutions to facilitate the transition of its innovative therapies from the laboratory to clinical application, ultimately striving to improve the quality of life for patients with limited treatment options.

United States

CentryMed is a biopharmaceutical company located in Frederick, Maryland, neighboring the National Cancer Institute (NCI) and numerous pioneering biotechnology companies and supporting entities. Since its founding in 2018, CentryMed has been dedicated to discovering and developing safer and more effective biotherapeutics for the treatment of various diseases.

CentryMed Pharmaceutical

Company Details